Whalesbook
Senores Pharmaceuticals Ltd has reported a strong fiscal year ended March 31, 2026, with Profit After Tax (PAT) surging 108% year-on-year to Rs 122 Crores. The company's total income for the year grew 65% to Rs 664 Crores. Performance in the fourth quarter also showed significant gains, with PAT increasing 104% to Rs 37 Crores on income up 66% to Rs 190 Crores. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the full year rose 114% to Rs 200 Crores.
In parallel with the financial update, Mr. Vinay Kumar Mishra has resigned as Company Secretary and Compliance Officer, with his resignation effective June 10, 2026. Sharp & Tannan Associates have been appointed as the company's Internal Auditors for the upcoming fiscal year 2026-27.
The robust financial performance highlights Senores Pharmaceuticals' strong operational execution and market traction. The substantial growth in income and profitability, particularly the doubling of PAT and significant EBITDA increase, reflects effective strategies and cost management.
The upcoming departure of the Company Secretary and Compliance Officer presents a key watchpoint for corporate governance. Ensuring a smooth transition and the timely appointment of a successor will be crucial for maintaining standards.
Senores Pharmaceuticals operates in the pharmaceutical formulations sector, manufacturing and marketing a range of products. The company previously secured funds through a preferential issue in March 2024, aiming to raise approximately Rs 20-25 crore to support its growth initiatives.
Within India's competitive pharmaceutical industry, Senores Pharmaceuticals' recent performance stands out. While peers like Aarti Drugs Ltd and Indoco Remedies Ltd are established players, Senores has demonstrated accelerated growth in FY26, surpassing them in percentage terms for PAT and revenue growth.
Looking ahead, investors will monitor the appointment of a new Company Secretary and Compliance Officer, as well as the performance and findings of the new internal auditors, Sharp & Tannan Associates. The company's ability to sustain its high growth trajectory in future quarters and any strategic announcements or new product launches planned for FY27 will also be key areas of focus.